AMT-116 for advanced non-squamous lung cancer after prior treatments
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug called AMT-116 for advanced lung cancer that has not responded to standard treatments. It compares AMT-116 to the doctor's choice of chemotherapy. If you qualify, you'll get either the new drug or a standard treatment, and the goal is to see which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have non-small cell lung cancer (NSCLC) that is advanced or has spread, and it must be a type called 'non-squamous'.
- Your tumor must not have a specific gene change called EGFR mutation.
- You need to have had at least one prior treatment for your lung cancer, including platinum-based chemotherapy and/or immunotherapy, and your cancer must have gotten worse after that.
- You should be able to do daily activities (ECOG score 0 or 1) and live at least 12 weeks.
- Your major organs (blood, kidneys, liver) must work well enough, based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AMT-116 in people with advanced solid tumors that have not responded to prior treatment. The goal is to see if it is safe and effective.
This Phase 1 trial tests AMT-116, an investigational medicine, in people with advanced solid cancers that can’t be removed by surgery and have gotten worse after standard treatment. It looks for the best safe dose and early signs the treatment may shrink tumors or slow growth.
This trial tests a combination of two experimental drugs (AMT-116 and ivosidan) for patients with advanced lung cancer that cannot be removed by surgery. The study aims to see if this combination can help shrink tumors and improve survival.
This trial tests a new drug called AMT-676 in people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers like colorectal, stomach, or pancreatic cancer.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
This study tests a new drug called JSKN016 in people with advanced non-small cell lung cancer whose standard treatments have stopped working. The drug may help shrink tumors or slow the cancer's growth, and the study looks at safety and effectiveness.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.